Seeing this deal was struck April 2018 and due in May 2019, this is where I see some wiggle room..."if the Clinical Steering Committee for the Phase III BETonMACE clinical trial determines, based on its planned sample size reestimation analysis, that it is advisable to enroll additional patients in the trial then the Borrower shall provide the Agent with top-line results from the trial as soon as practicable."

IMO...Koo